Cargando…
349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19
BACKGROUND: Patients with COVID-19 receive high rates of antibiotic therapy, despite viral origin of infection. Reports of bacterial coinfection range from 3.5 to 8% in the early phase of infection. This study aimed to evaluate the relationship between diagnostic tests and antibiotic utilization in...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643796/ http://dx.doi.org/10.1093/ofid/ofab466.550 |
_version_ | 1784609935726739456 |
---|---|
author | Groft, Lauren Opran, Iulia Tadesse, Yeabsera Vo, Hang Heil, Emily Heil, Emily Schrank, Gregory Claeys, Kimberly C |
author_facet | Groft, Lauren Opran, Iulia Tadesse, Yeabsera Vo, Hang Heil, Emily Heil, Emily Schrank, Gregory Claeys, Kimberly C |
author_sort | Groft, Lauren |
collection | PubMed |
description | BACKGROUND: Patients with COVID-19 receive high rates of antibiotic therapy, despite viral origin of infection. Reports of bacterial coinfection range from 3.5 to 8% in the early phase of infection. This study aimed to evaluate the relationship between diagnostic tests and antibiotic utilization in patients admitted with COVID-19 at the University of Maryland Medical Center to better inform future prescribing practices. METHODS: Retrospective cohort study of adult patients with a positive SARS-CoV-2 PCR on admission from March 2020 through June 2020. Associations between diagnostic tests employed and antibiotic initiation and duration were explored using bivariate analysis (SPSS®). RESULTS: Baseline characteristics of 224 included patients are reported in Table 1. Excluding SARS-CoV-2 PCRs, most frequently performed diagnostic tests included blood cultures (65.6%), MRSA nasal surveillance (45.1%), respiratory cultures (36.2%), respiratory viral panel (RVP) (33.0%), and Legionella (28.6%) and pneumococcal (26.3%) urine antigens. Positivity of RVP, Legionella, pneumococcus, blood, and respiratory tests were low (1.3%, 0.4%, 0.9%, 1.8%, and 6.7%, respectively). A total of 62% of patients were initiated on antibacterial therapy with a median cumulative antibiotic duration of 77.9 hours (IQR 41.4, 111.8). History of chronic respiratory disease (76% vs. 58.6%; P=0.025), any degree of oxygen requirement on admission (72% vs. 42.6%; P=0.006), and performance of blood cultures (70.7% vs. 46.8%, P< 0.0001) were associated with antibiotic initiation. Positive bacterial diagnostic respiratory culture (median duration 72.8h [IQR 46.7, 96.6] vs. 97.3h [IQR 79.8, 194.1]; P=0.027) and positive blood culture (median duration 80.1h [IQR 42.1, 111.7] vs. 97.5h [IQR 71.8, 164.8]; P=0.046) were associated with longer antibiotic duration. Patients who did not have respiratory cultures performed had similar antibiotic durations as those with negative respiratory cultures. Table 1. Baseline Characteristics [Image: see text] CONCLUSION: Despite low coinfection rates, negative diagnostic tests did not result in shorter empiric antibacterial duration. These findings highlight the ongoing need for both diagnostic and antimicrobial stewardship in COVID-19. DISCLOSURES: Emily Heil, PharmD, MS, BCIDP, Nothing to disclose Kimberly C. Claeys, PharmD, GenMark (Speaker’s Bureau) |
format | Online Article Text |
id | pubmed-8643796 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-86437962021-12-06 349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19 Groft, Lauren Opran, Iulia Tadesse, Yeabsera Vo, Hang Heil, Emily Heil, Emily Schrank, Gregory Claeys, Kimberly C Open Forum Infect Dis Poster Abstracts BACKGROUND: Patients with COVID-19 receive high rates of antibiotic therapy, despite viral origin of infection. Reports of bacterial coinfection range from 3.5 to 8% in the early phase of infection. This study aimed to evaluate the relationship between diagnostic tests and antibiotic utilization in patients admitted with COVID-19 at the University of Maryland Medical Center to better inform future prescribing practices. METHODS: Retrospective cohort study of adult patients with a positive SARS-CoV-2 PCR on admission from March 2020 through June 2020. Associations between diagnostic tests employed and antibiotic initiation and duration were explored using bivariate analysis (SPSS®). RESULTS: Baseline characteristics of 224 included patients are reported in Table 1. Excluding SARS-CoV-2 PCRs, most frequently performed diagnostic tests included blood cultures (65.6%), MRSA nasal surveillance (45.1%), respiratory cultures (36.2%), respiratory viral panel (RVP) (33.0%), and Legionella (28.6%) and pneumococcal (26.3%) urine antigens. Positivity of RVP, Legionella, pneumococcus, blood, and respiratory tests were low (1.3%, 0.4%, 0.9%, 1.8%, and 6.7%, respectively). A total of 62% of patients were initiated on antibacterial therapy with a median cumulative antibiotic duration of 77.9 hours (IQR 41.4, 111.8). History of chronic respiratory disease (76% vs. 58.6%; P=0.025), any degree of oxygen requirement on admission (72% vs. 42.6%; P=0.006), and performance of blood cultures (70.7% vs. 46.8%, P< 0.0001) were associated with antibiotic initiation. Positive bacterial diagnostic respiratory culture (median duration 72.8h [IQR 46.7, 96.6] vs. 97.3h [IQR 79.8, 194.1]; P=0.027) and positive blood culture (median duration 80.1h [IQR 42.1, 111.7] vs. 97.5h [IQR 71.8, 164.8]; P=0.046) were associated with longer antibiotic duration. Patients who did not have respiratory cultures performed had similar antibiotic durations as those with negative respiratory cultures. Table 1. Baseline Characteristics [Image: see text] CONCLUSION: Despite low coinfection rates, negative diagnostic tests did not result in shorter empiric antibacterial duration. These findings highlight the ongoing need for both diagnostic and antimicrobial stewardship in COVID-19. DISCLOSURES: Emily Heil, PharmD, MS, BCIDP, Nothing to disclose Kimberly C. Claeys, PharmD, GenMark (Speaker’s Bureau) Oxford University Press 2021-12-04 /pmc/articles/PMC8643796/ http://dx.doi.org/10.1093/ofid/ofab466.550 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Poster Abstracts Groft, Lauren Opran, Iulia Tadesse, Yeabsera Vo, Hang Heil, Emily Heil, Emily Schrank, Gregory Claeys, Kimberly C 349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19 |
title | 349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19 |
title_full | 349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19 |
title_fullStr | 349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19 |
title_full_unstemmed | 349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19 |
title_short | 349. Diagnostic Testing and Antibiotic Utilization in Patients with COVID-19 |
title_sort | 349. diagnostic testing and antibiotic utilization in patients with covid-19 |
topic | Poster Abstracts |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643796/ http://dx.doi.org/10.1093/ofid/ofab466.550 |
work_keys_str_mv | AT groftlauren 349diagnostictestingandantibioticutilizationinpatientswithcovid19 AT opraniulia 349diagnostictestingandantibioticutilizationinpatientswithcovid19 AT tadesseyeabsera 349diagnostictestingandantibioticutilizationinpatientswithcovid19 AT vohang 349diagnostictestingandantibioticutilizationinpatientswithcovid19 AT heilemily 349diagnostictestingandantibioticutilizationinpatientswithcovid19 AT heilemily 349diagnostictestingandantibioticutilizationinpatientswithcovid19 AT schrankgregory 349diagnostictestingandantibioticutilizationinpatientswithcovid19 AT claeyskimberlyc 349diagnostictestingandantibioticutilizationinpatientswithcovid19 |